Compare PCN & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCN | CDNA |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 846.9M | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | PCN | CDNA |
|---|---|---|
| Price | $12.82 | $19.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 218.7K | ★ 722.8K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 9.73% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | N/A | ★ $357,998,000.00 |
| Revenue This Year | N/A | $14.11 |
| Revenue Next Year | N/A | $11.75 |
| P/E Ratio | ★ N/A | $15.75 |
| Revenue Growth | N/A | ★ 14.46 |
| 52 Week Low | $10.70 | $10.96 |
| 52 Week High | $14.48 | $25.95 |
| Indicator | PCN | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 60.33 |
| Support Level | $12.66 | $18.75 |
| Resistance Level | $12.82 | $20.61 |
| Average True Range (ATR) | 0.08 | 0.73 |
| MACD | 0.03 | -0.17 |
| Stochastic Oscillator | 94.12 | 52.07 |
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.